Asset profile
mazdutide
Peptide
Evidence outlook · lead readout
DREAMS-2 (NCT05606913) · Type 2 Diabetes
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
DREAMS-2 (NCT05606913): This was a randomized, double-blind, active-controlled trial of 731 people with type 2 diabetes. Both mazdutide doses lowered blood sugar (HbA1c) significantly more than the comparator drug dulaglutide, a difference that reached statistical significance.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Obesity · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
117 competitors in this universe: 4 direct rivals (same mechanism and indication), 2 same-class, 111 same-indication; 38 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Mazdutide: this drug | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| AZD9550 | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| PB-718 | Phase 1/2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| DA-1726 | Phase 1 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| OPK-88006 | Phase 1/2 | — | GLP-1/glucagon receptor (dual) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) |
…and 102 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (7)
May 2027 (1)
September 2027 (2)
October 2027 (1)
December 2027 (3)
What to watch
What to watch
What to watch
2028 (5)
May 2028 (1)
What to watch
June 2028 (2)
August 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (5)
February 2029 (2)
What to watch
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.